EUCTR2017-003159-44-ES进行中（未招募）1 期
Phase II trial of durvalumab (Medi4736) plus tremelimumab with concurrent radiotherapy in patients with localized muscle invasive bladder cancer treated with a selective bladder preservation approach - INMUNOPRESERVE
Spanish Oncology Genitourinary Group0 个研究点目标入组 32 人开始时间: 2018年6月21日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients diagnosed with urothelial carcinoma of the bladder, in clinical stages T2-4a N0 M0, who are
- •not candidates for radical cystectomy by medical reasons, refusal or patient’s choice.
- •1. Patients must have signed the informed consent prior to undergoing any study procedure.
- •2. Patients must be 18 years of age or older.
- •3. Patients must have ECOG performance status 0 or 1.
- •4. A paraffin-embedded tumor sample must be available for the associate molecular study.
- •5. Body weight >30 Kg.
- •6. Adequate normal organ and marrow function as defined in section 4.1 of this protocol.
- •7. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients, according to what is detailed in section 4.1 of this protocol.
- •8. Patient is willing and able to comply with the protocol for the duration of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 32
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 32
排除标准
- •1. Involvement in the planning and/or conduct of the study (applies to both Sponsor staff and/or
- •staff at the study site)
- •2. Participation in another clinical study with an investigational product during the last 30 days.
- •3. Concurrent enrolment in another clinical study unless it is an observational (non-interventional)
- •clinical study or during the follow-up period of an interventional study.
- •4. Previous treatment with radiotherapy to the bladder, systemic chemotherapy or immune checkpoint inhibitors. Prior intravesical Bacillus Calmette-Guérin (BCG) treatment for non- muscle invasive bladder cancer is allowed, 28 days prior to study.
- •5. Presence of regional lymph node or metastatic extension of the disease.
- •6. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) =470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart) <>.
- •7. Any unresolved toxicity NCI CTCAE Grade =2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. Patients with Grade =2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.
- •8. Any concurrent chemotherapy, investigational product (IP) other than studied in this protocol, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non–cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
- •9. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
- •10. History of allogenic organ transplantation.
- •11. Active or prior documented autoimmune or inflammatory disorders, as it is detailed in section 4.2 of this protocol.
- •12. Uncontrolled intercurrent illness, please see section 4 of this protocol.
- •13. History of another primary malignancy as detailed in section 4 of this protocol.
- •14. History of active primary immunodeficiency
- •15. Active infection (see section 4 of this protocol)
- •16. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. Exceptions are listed in section 4 of this protocol.
- •17. Receipt of live attenuated vaccine within 30 days prior to the first dose of IMP
- •18. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control according what is detailed in this protocol (section 4).
- •19. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
- •20. Prior randomisation or treatment in a previous durvalumab and/or tremelimumab clinical study.
- •21. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.
- •22. Known allergy or hypersensi
研究者
相似试验
已完成
2 期
on small cell lung cancer trial of durvalumab and tremelimumab in advanced epidermal growth factor receptor (EGFR) mutant disease.EGFR mutant advanced non small cell lung cancer.Cancer - Lung - Non small cellACTRN12618001742268niversity of Sydney100
招募中
2 期
Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)2024-515240-24-00Grupo Espanol Multidisciplinar En Cancer Digestivo60
终止
1 期
Cetuximab immunotherapy combination in head and neck cancerCancerISRCTN89314418The Christie NHS Foundation Trust36
进行中（未招募）
1 期
Durvalumab plus tremelimumab for progressive, refractory advanced thyroid carcinomaAdvanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary,follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC).Advanced medullary thyroid carcinoma (MTC)Advanced anaplastic thyroid cancer (ATC)MedDRA version: 20.0Level: PTClassification code 10076603Term: Poorly differentiated thyroid carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10002240Term: Anaplastic thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10016935Term: Follicular thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10071027Term: Thyroid cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10071028Term: Thyroid cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001066-42-ESSpanish Group of Neuroendocrine Tumors (GETNE)84
进行中（未招募）
1 期
Durvalumab plus Tremelimumab for gastrointestinal-pancreatic or advanced pulmonar tumoursAdvanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin.MedDRA version: 19.1Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 100000004864EUCTR2016-002858-20-ESGETNE (Grupo Español de Tumores Neuroendocrinos)